Should clinicians follow the K/DOQI guidelines for treating hyperphosphatemia with sevelamer?-Reference-Cited by-同舟云学术

Should clinicians follow the K/DOQI guidelines for treating hyperphosphatemia with sevelamer?

Published:2007-06-12 Issue:8 Volume:3 Page:418-419
ISSN:1745-8323
Container-title:Nature Clinical Practice Nephrology
language:en
Short-container-title:Nat Rev Nephrol

Author:

Komaba Hirotaka,Fukagawa Masafumi

Publisher

Springer Science and Business Media LLC

Subject

Nephrology,General Medicine

Link

http://www.nature.com/articles/ncpneph0536.pdf

Reference7 articles.

1. Chertow GM et al. (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245–252

2. Block GA et al. (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815–1824

3. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3) : S1–S201

4. Manns B et al. (2004) A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66: 1239–1247

5. Block GA et al. (2007) Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438–441

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daily on line haemodiafiltration promotes catch-up growth in children on chronic dialysis;Nephrology Dialysis Transplantation;2009-11-04

2. Towards Cost-effective Strategies for Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Japan;Therapeutic Apheresis and Dialysis;2009-10